Full Breakdown
Eli Lilly's Critique of UK Drug Pricing: A Call for Change
9/24/2025, 8:42:42 PM
Eli Lilly's Concerns Over UK Drug Prices
Eli Lilly's Chief Executive Officer, Dave Ricks, has publicly criticized the United Kingdom's drug pricing policies, labeling the country as "probably the worst in Europe" for pharmaceutical pricing. His remarks, made in an interview with the Financial Times, highlight a growing discontent among major pharmaceutical companies regarding the UK's stringent pricing regime, which Ricks argues is detrimental to both investment and patient access to new medications. He emphasized that unless the UK raises drug prices and abolishes the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), the country risks missing out on new drug introductions and further investments.
Background on the VPAG Scheme
The VPAG scheme, designed to manage NHS drug costs, requires pharmaceutical companies to contribute a portion of their revenues back to the state-run health service when sales exceed certain thresholds. This year, the rebate has surged to nearly 23%, a significant increase from previous years, which Ricks claims punishes companies for their success. The deadlock in negotiations between the pharmaceutical industry and the UK government over this scheme has led to a notable decline in investment, with major companies like Merck and AstraZeneca halting or canceling significant projects in the UK.
Impact on Pharmaceutical Investments
The backlash against the UK's drug pricing policies has resulted in substantial financial repercussions for the pharmaceutical sector. Reports indicate that nearly £2 billion in planned investments have been suspended or canceled this year alone. For instance, Merck scrapped a £1 billion research hub in London, while AstraZeneca paused a £200 million expansion in Cambridge. Eli Lilly itself has temporarily halted shipments of its weight-loss drug Mounjaro to the UK, citing the need to adjust prices significantly—up to 170% for private buyers.
Official Responses and Industry Reactions
In response to Ricks's comments, a UK government spokesperson stated that the administration is committed to making the UK an attractive destination for life sciences investment and is open to future discussions with the industry. However, the ongoing tensions suggest a challenging environment for negotiations. The government has previously made offers to boost health spending, but these have not resolved the underlying issues regarding drug pricing.
Criticism and Opposition
Critics of the current UK drug pricing model argue that it undermines the country's ability to attract and retain pharmaceutical investments. Industry leaders have expressed concerns that the UK's approach could lead to a shortage of innovative treatments for patients. Ricks's assertion that "it is not an attractive environment" for investment reflects a broader sentiment among pharmaceutical executives who feel squeezed by the current pricing structure.
What's Next for the UK Pharmaceutical Landscape
As the deadline for U.S. pharmaceutical companies to comply with President Donald Trump's most favored nation pricing policy approaches, the pressure on UK drug pricing will likely intensify. Companies are expected to continue advocating for higher prices in the UK to offset potential losses in the U.S. market. The outcome of these negotiations and the future of the VPAG scheme will be critical in determining the UK's position in the global pharmaceutical landscape.
Verbatim Quotes
- “Unless that changes, I don’t think they will see many new medicines and I don't think they will see much investment.” — Dave Ricks, CEO of Eli Lilly
- “Mr Ricks said: "What we had seen is people taking trains from Paris to buy UK Mounjaro.” — Dave Ricks, CEO of Eli Lilly
- “We agree with the Trump administration that other countries need to pay their fair share,” — Adam Lenkowsky, Chief Commercial Officer at Bristol Myers Squibb
The ongoing discourse surrounding drug pricing in the UK underscores the delicate balance between ensuring patient access to medications and maintaining a viable investment climate for pharmaceutical companies.
